Entries by PR Newswire

,

Cantrixil Receives Orphan Drug Designation from FDA

SYDNEY, April 21, 2015 /PRNewswire/ — US-Australian drug discovery company, Novogen, today announced that its subsidiary joint venture company with Yale University, CanTx, Inc, has today received notification from the U.S. Food and Drug Administration (FDA) that its chemotherapy candidate drug, Cantrixil, has been granted Orphan Drug Designation for ovarian cancer. Orphan Drug Designation is an important […]

,

U.S. Census Bureau Daily Feature for April 21

WASHINGTON, April 21, 2015 /PRNewswire-USNewswire/ — Following is the daily “Profile America” feature from the U.S. Census Bureau: LIFESAVING MEDICINE Profile America — Tuesday, April 21st. One of world’s most important medicines — insulin —became available for general use this month in 1923, saving the lives of millions of people suffering from diabetes. Insulin is a hormone […]

Eli Lilly’s Ixekizumab Succeeds in Late-Stage Study

INDIANAPOLIS, April 20, 2015 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the investigational medicine ixekizumab was statistically superior to placebo in the treatment of patients with active psoriatic arthritis (PsA), as demonstrated by the proportion of patients achieving an ACR 20 response. ACR 20 is a standard assessment that represents a […]

Aon Analysis Shows Double-Digit Increases in U.S. Pharmacy Costs by 2016

LINCOLNSHIRE, Ill., April 20, 2015 /PRNewswire/ — U.S. pharmacy cost increases for active employees and pre- and post-65 retirees are expected to drift into the low double-digits by 2016, according to an analysis by Aon Hewitt, the global talent, retirement and health solutions business of Aon plc (NYSE: AON). Pharmacy cost increases before plan design changes […]

,

Oasmia’s Lead Cancer Product Paclical Receives Market Approval in the Russian Federation

UPPSALA, Sweden, April 20, 2015 /PRNewswire/ — Paclical, a novel formulation of paclitaxel based on Oasmia’s XR-17 technology, was approved for treatment of (i.e., it received market authorization for) epithelial ovarian cancer in combination with carboplatin. XR-17 is non-toxic and forms water soluble nanoparticles with paclitaxel.      (Logo: http://photos.prnewswire.com/prnh/20150420/740096 )  The Russia-based company Pharmasyntez holds the […]

,

New SU2C-American Cancer Society Lung Cancer Dream Team Announced

PHILADELPHIA, April 20, 2015 /PRNewswire-USNewswire/ — Stand Up To Cancer (SU2C) and the American Cancer Society (ACS) announced the formation of a $20 million Dream Team to attack the number one cancer killer in America, lung cancer, here today at the Annual Meeting of the American Association for Cancer Research (AACR), Scientific Partner to SU2C. ACS […]

,

Restrictive Drug Plan Regulations Will Hurt Patients

DALLAS, April 20, 2015 /PRNewswire-USNewswire/ — Increasing unnecessary regulations on drug plans could inflict higher costs on the 220 million Americans who get their medications through a managed drug plan, according to a  new report by National Center for Policy Analysis Senior Fellow Devon Herrick. “The degree to which drug benefit plans are managed efficiently […]

, ,

Lupin Launches Zaxine in Canada

MUMBAI and MONTREAL, April 20, 2015 /PRNewswire/ — Zaxine 550mg (rifaximin) is a long term antibiotic treatment for adults living with hepatic encephalopathy (HE), a complication of liver disease (cirrhosis). HE can lead to a wide spectrum of mental and physical symptoms, including confusion, disruption in sleep patterns, personality changes and coma Zaxine® 550mg has approved by […]

Study shows new technology may improve management of leading causes of blindness

PORTLAND, Ore., April 20, 2015 /PRNewswire/ — Research published today in the Proceedings of the National Academy of Sciences (PNAS) demonstrates that technology invented by researchers at Oregon Health & Science University’s Casey Eye Institute can improve the clinical management of the leading causes of blindness. Optical coherence tomography (OCT) angiography could largely replace current dye-based […]

Extending Treatment Up To Eight Weeks With Infusion Medication Shown Safe And Effective In Patients With Multiple Sclerosis

NEW YORK, April 20, 2015 /PRNewswire-USNewswire/ — Extending the dose of an infusion medication for multiple sclerosis (MS) from 4 weeks up to 8 has been shown to be well-tolerated and effective — and resulted in no cases of the potentially fatal side effect, progressive multifocal leukoencephalopathy (PML), according to a new study led by researchers […]